Ectopic PDX-1 expression in liver ameliorates type 1 diabetes

Area of Science:

• Endocrinology
• Immunology
• Gene Therapy

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease causing pancreatic beta-cell destruction.
• Previous attempts to restore pancreatic function using liver-derived cells faced challenges with autoimmune attack.
• PDX-1 gene therapy offers a potential strategy to regenerate beta-cells.

Purpose of the Study:

• To investigate the efficacy of Ad-CMV-PDX-1 gene therapy in ameliorating autoimmune Type 1 diabetes.
• To assess if PDX-1 gene therapy can overcome autoimmune attack in a relevant animal model.

Main Methods:

• Utilized cyclophosphamide-accelerated diabetes in non-obese diabetic (CAD-NOD) mice model.
• Administered recombinant adenovirus mediated PDX-1 gene therapy.
• Analyzed glycemic control, body weight, pancreatic gene expression, insulin production, and immune response.

Main Results:

• Ad-CMV-PDX-1 gene therapy normalized blood glucose in 43% of overtly diabetic CAD-NOD mice.
• Ectopic PDX-1 expression in the liver induced pancreatic gene expression and insulin production.
• Treatment was associated with immune modulation, shifting T-cell response from Th1 to Th2.

Conclusions:

• Liver-to-pancreas transdifferentiation via PDX-1 gene therapy shows therapeutic potential for autoimmune Type 1 diabetes.
• The therapy ameliorates hyperglycemia and modulates the autoimmune attack, suggesting a dual benefit.
• PDX-1 gene therapy is a promising strategy for treating autoimmune T1DM.